ÂíÀ´Î÷ÑÇÒ½Éúѭ֤ҽѧ֪¶àÉÙ£¿¡ª¡ª ̽Ë÷֪ʶ¡¢Êµ¼ùÓë´Ù½øÒòËØ£¬½âËøÒ½Áƾö²ßÐÂÃÜÂë

¡¾×ÖÌ壺 ´ó ÖРС ¡¿ ʱ¼ä£º2025Äê02ÔÂ20ÈÕ À´Ô´£ºBMC Medical Education 2.7

±à¼­ÍƼö£º

¡¡¡¡ÎªÁ˽âÂíÀ´Î÷ÑÇÒ½Éú EBM µÄ֪ʶ¡¢Êµ¼ù¡¢´Ù½øÒòËØ¼°Ïà¹ØÒòËØ£¬ÂíÀ´Î÷ÑÇÁÙ´²Ñо¿ÖÐÐĵÄÑо¿ÈËÔ±¿ªÕ¹Ïà¹ØÑо¿¡£½á¹û·¢ÏÖÒ½Éú EBM ֪ʶÖеȡ¢Êµ¼ù½Ï¸ßµÈ¡£¸ÃÑо¿ÄÜÖúÁ¦¸ÄÉÆ EBM ʵʩ£¬ÍƼö¿ÆÑжÁÕßÒ»¶Á¡£

¡¡¡¡
ÔÚҽѧÁìÓò£¬ÁÙ´²¾ö²ß¶ÔÓÚ»¼ÕßµÄÖÎÁÆÐ§¹ûÆð×ÅÖÁ¹ØÖØÒªµÄ×÷Ó᣶øÖ¤¾Ý - based medicine£¨EBM£¬Ñ­Ö¤Ò½Ñ§£©£¬¼òµ¥À´Ëµ£¬¾ÍÊÇÔÚΪ»¼Õß½øÐÐÖÎÁƾö²ßʱ£¬Òª½÷É÷¡¢Ã÷È·ÇÒÃ÷ÖǵØÔËÓõ±Ç°×î¼ÑµÄÖ¤¾Ý£¬Ëü½«Ò½Éú¸öÈ˵ÄÁÙ´²¾­Ñ顢ϵͳÑо¿µÃ³öµÄ×î¼ÑÍⲿÁÙ´²Ö¤¾ÝÒÔ¼°»¼ÕߵļÛÖµ¹ÛºÍÆ«ºÃÕûºÏÔÚÒ»Æð£¬¶ÔÌá¸ßÒ½ÁÆÖÊÁ¿ºÍ»¼ÕßÖÎÁÆÐ§¹ûÓÐ׏ؼü×÷Óá£

ÔÚÂíÀ´Î÷ÑÇ£¬Õþ¸®Ò»Ö±ÔÚŬÁ¦Íƹã EBM£¬³«µ¼Ê¹ÓÃÑ­Ö¤ÁÙ´²Êµ¼ùÖ¸ÄÏ¡£È»¶ø£¬ÂíÀ´Î÷ÑÇÒ½Éú¶Ô EBM µÄʵ¼ÊÓ¦ÓÃÇé¿öÈ´²¢²»Ã÷È·¡£Ö®Ç°Óв»ÉÙÑо¿¶ÔÂíÀ´Î÷ÑÇÒ½Éú¹ØÓÚ EBM µÄ֪ʶ¡¢Êµ¼ù¡¢ÊµÊ©Õϰ­¼°Ïà¹ØÒòËØ½øÐÐÁËÆÀ¹À£¬µ«ÕâЩÑо¿´ó¶à¾ÖÏÞÓÚÌØ¶¨µÄµØÀíÇøÓò»òÒ½ÁÆ»·¾³£¬ÎÞ·¨È«ÃæÕ¹ÏÖÂíÀ´Î÷ÑÇÒ½Éú EBM µÄʵʩÇé¿ö¡£±ÈÈç˵£¬ÓеÄÑо¿·¢ÏÖ£¬ÔÚÂíÀ´Î÷ÑÇÑ©À¼Ý­ÖÝµÄ 225 Ãû³õ¼¶±£½¡Ò½ÉúÖУ¬Ö»ÓÐ 32.9% µÄÈËÓиßˮƽµÄ EBM ֪ʶ£¬ÇÒ 84% µÄÈË EBM ʵ¼ùÇé¿ö²»¼Ñ£»ÔÚ¼ªÀ¼µ¤ÖÝµÄ 183 Ãû¼±ÕïÒ½ÉúÖУ¬49.7% µÄÈËÓÐ¸ß EBM ֪ʶ£¬µ«Ö»ÓÐ 15.6% µÄÈËÔÚʵ¼ùÖÐÓ¦ÓÃÁË EBM ¡£¶øÇÒ£¬Ò½ÉúÃÇÔÚʵʩ EBM ʱ»¹ÃæÁÙ×ÅÖî¶àÕϰ­£¬Ïñȱ·¦Ê±¼ä¡¢ÍøÂç·ÃÎÊÊÜÏÞ¡¢¶Ôͳ¼ÆÑ§Àí½â²»×ãµÈ¡£

ΪÁ˸üÈ«Ãæ¡¢ÉîÈëµØÁ˽âÂíÀ´Î÷ÑÇÒ½Éú¶Ô EBM µÄÕÆÎÕºÍÓ¦ÓÃÇé¿ö£¬À´×ÔÂíÀ´Î÷ÑÇÁÙ´²Ñо¿ÖÐÐÄ£¨Hospital Seberang Jaya£©µÈ»ú¹¹µÄ Stephenie Ann Albart ºÍ Irene Looi µÈÑо¿ÈËÔ±£¬ÔÚ¡¶BMC Medical Education¡·ÆÚ¿¯ÉÏ·¢±íÁËһƪÃûΪ ¡°Knowledge, practice, and facilitating factors of evidence?based medicine among Malaysian doctors: a cross?sectional study¡± µÄÂÛÎÄ¡£Í¨¹ýÕâÏîÑо¿£¬ËûÃǵóöÁ˲»ÉÙÖØÒª½áÂÛ£¬Õâ¶ÔÓÚ´Ù½øÂíÀ´Î÷ÑÇ EBM µÄʵʩÓÐ×ÅÖØÒªÒâÒå¡£

ÔÚÑо¿·½·¨ÉÏ£¬Ñо¿ÈËÔ±²ÉÓÃÁ˺á¶ÏÃæÑо¿£¨cross-sectional study£©µÄ·½·¨£¬ÔÚ 2022 Äê 6 ÔÂÖÁ 11 ÔÂÆÚ¼ä£¬Í¨¹ýÍøÂç¶ÔÂíÀ´Î÷ÑǸ÷µØµÄÒ½Éú½øÐÐÁ˵÷²é¡£ËûÃÇÀûÓþ­¹ýÑéÖ¤µÄ Evidence-Based Medicine Questionnaire£¨EBMQ£¬Ñ­Ö¤Ò½Ñ§ÎÊ¾í£©À´ÊÕ¼¯Êý¾Ý£¬ÆÀ¹ÀÒ½ÉúÃÇ¶Ô EBM µÄÖªÊ¶ÕÆÎÕ£¨Knowledge£©¡¢Êµ¼ùÓ¦Óã¨Practice£©ÒÔ¼°´Ù½øÒòËØ£¨Facilitating factors£©Çé¿ö¡£Ö®ºó£¬ÔËÓà SPSS 28 Èí¼þ½øÐÐÊý¾Ý·ÖÎö£¬ÏñÓà Pearson Ïà¹ØÏµÊýÀ´ºâÁ¿ÖªÊ¶¡¢Êµ¼ùºÍ´Ù½øÒòËØÖ®¼äµÄÏà¹ØÐÔ£¬Í¨¹ý¶àÒòËØ¶à±äÁ¿Ð­·½²î·ÖÎö£¨MANCOVA£©À´Ñо¿²»Í¬ÒòËØ¶Ô EBM ֪ʶºÍʵ¼ùµÃ·ÖµÄÓ°Ïì ¡£

ÏÂÃæÀ´¿´¿´¾ßÌåµÄÑо¿½á¹û¡£

ÊÜ·ÃÕßÌØÕ÷


¹²ÓÐ 409 ÃûÀ´×ÔÂíÀ´Î÷ÑǸ÷µØµÄÒ½Éú²ÎÓëÁË´Ë´ÎÔÚÏßµ÷²é¡£ÕâЩҽÉú´ó¶à´¦ÓÚÖ°ÒµÉúÑÄÖÐÆÚ£¬ÄêÁäÖÐλÊýÔÚ 30 ¶àË꣬´ÓÒµ¾­ÑéÔ¼ 9 Äê¡£ÆäÖÐÅ®ÐÔÕ¼±È 57.7%£¬·Çר¿ÆÒ½ÉúÕ¼ 72.1%£¬³¬¹ý°ëÊýÔÚÒ½Ôº¹¤×÷£¨59.9%£©£¬´ó²¿·Ö¾ÍÖ°ÓÚ¹«¹²²¿ÃÅ£¨82.2%£© ¡£¶øÇÒ£¬³¬¹ý°ëÊýÒ½ÉúûÓÐÑо¿ÉúѧÀú£¨54%£©£¬½üÈý·ÖÖ®¶þûÓвμӹý EBM ÑÐÌֻᣨ64.3%£©£¬Ô¼ 60% ÓбÏÒµºóµÄÑо¿¾­Ñ飬µ« 65% ûÓÐѧÊõ³ö°æÎï¡£

EBM ֪ʶ


ÔÚ EBM ÐÅÏ¢À´Ô´·½Ã棬ҽÉúÃÇ¶Ô EBM ÆÚ¿¯µÄÈÏÖªºÍʹÓÃÂʽϸߣ¬Ïñ BMJ EBM ºÍ BMJ Clinical Evidence ÕâÁ½ÖÖÆÚ¿¯£¬Ò»°ëµÄÊÜ·ÃÕß»áÔÚÁÙ´²¾ö²ßÖÐʹÓã¬Ö»ÓÐÉÙÊýÈË£¨×î¶à 10.5%£©²»ÖªµÀÕâÁ½ÖÖÆÚ¿¯¡£È»¶ø£¬ËûÃÇ¶Ô EBM ÍøÕ¾µÄʹÓÃÂÊÈ´ºÜµÍ£¬Ö»ÓÐ 3.2% - 11.7% µÄÈË»áÔÚÁÙ´²¾ö²ßÖÐʹÓ㬳¬¹ý°ëÊýµÄÈËÉõÖÁ²»ÖªµÀÕâÐ©ÍøÕ¾µÄ´æÔÚ¡£ÔÚ¶ÔÑо¿ÀàÐÍºÍ EBM Ïà¹ØÊõÓïµÄÁ˽âÉÏ£¬Ëæ»ú¶ÔÕÕÊÔÑ飨RCT£©ÊÇÒ½ÉúÃÇ×îÁ˽âµÄÑо¿Éè¼ÆÀàÐÍ£¬91.7% µÄÈËÄÜÀí½â£¬52.8% µÄÈËÄܺܺõؽâÊÍ¡£¶øÏñÒìÖÊÐÔ£¨Heterogeneity£©ÕâÀิÔÓÊõÓÀí½âºÍ½âÊ͵ıÈÀýÏà¶Ô½ÏµÍ£¬·Ö±ðΪ 60.1% ºÍ 21.5% ¡£×ÜÌåÀ´Ëµ£¬Ò½ÉúÃÇ¶Ô EBM »ù´¡ÖªÊ¶ÓÐÒ»¶¨ÕÆÎÕ£¬µ«ÈÔÓÐÌáÉý¿Õ¼ä¡£

EBM ʵ¼ù


´Óµ÷²é½á¹ûÀ´¿´£¬´ó²¿·ÖÒ½Éú¶Ô EBM ʵ¼ù³Ö»ý¼«Ì¬¶È¡£³ýÁË ¡°EBM ¼õÉÙÎҵŤ×÷Á¿¡± ÕâÒ»±íÊöÓÐÕùÒéÍ⣨50.9% µÄÈËͬÒ⣬39.4% µÄÈ˳ÖÖÐÁ¢Ì¬¶È£©£¬¶ÔÓÚÆäËû¹ØÓÚ EBM ʵ¼ùµÄ±íÊö£¬´ó¶àÒ½Éú¶¼±íʾÈÏͬ£¨84.8% - 96.1%£© ¡£×ÛºÏÆÀ¹À£¬67.2% µÄÒ½Éú EBM ʵ¼ùµÃ·Ö½Ï¸ß£¬´¦ÓÚ¸ßˮƽ¡£

EBM ´Ù½øÒòËØºÍÕϰ­


ÔÚ´Ù½øÒòËØ·½Ãæ£¬ÍøÂç½ÓÈëÊÇÖ÷ÒªµÄ´Ù½øÒòËØ£¬81.4% µÄÊÜ·ÃÕß±íʾÄܽÓÈëÍøÂçÓÃÓÚ EBM ʵ¼ù¡£µ«Ê±¼ä²»×ãÊÇÃ÷ÏÔµÄÕϰ­£¬Ö»ÓÐ 39.1% µÄÈËÈÏΪ×Ô¼ºÓÐʱ¼äÔĶÁÑо¿ÂÛÎÄ¡£ÔÚ»¼Õ߯«ºÃ·½Ã棬ҽÉúÃǵĿ´·¨²»Ò»£¬33.9% - 51.1% µÄÈËÈÏΪ»¼Õ߯«ºÃ EBM ʵ¼ù²¢ÏàÐÅÏà¹ØÐÅÏ¢£¬µ«Ò²ÓÐ 41.8% - 57.7% µÄÈ˲»È·¶¨¡£²»¹ý£¬ÔÚͬʺÍ×éÖ¯Ö§³Ö·½Ãæ±íÏֽϺ㬳¬¹ý 70% µÄÒ½ÉúÈÏΪͬʺÍ×éÖ¯Ö§³Ö EBM ʵ¼ù¡£

×ÜÌå EBM ֪ʶ¡¢Êµ¼ùºÍ´Ù½øÒòËØ


ÕûÌåÀ´¿´£¬Ò½ÉúÃÇµÄ EBM ʵ¼ùÁìÓòƽ¾ù×ܰٷֱȵ÷Ö×î¸ß£¬Îª 83.7%£¬ÊôÓÚ¸ßˮƽ£»ÖªÊ¶ºÍ´Ù½øÒòËØÁìÓòµÄƽ¾ù×ܰٷֱȵ÷ִóÖÂÏàͬ£¬¾ùΪ 71%£¬´¦ÓÚÖеÈˮƽ¡£½øÒ»²½·ÖÎö·¢ÏÖ£¬ÖªÊ¶¡¢Êµ¼ùºÍ´Ù½øÒòËØµÃ·ÖÖ®¼ä´æÔÚÏÔÖøÕýÏà¹Ø ¡£

Óë EBM ֪ʶºÍʵ¼ùÏà¹ØµÄÒòËØ


Ñо¿·¢ÏÖ£¬²Î¼Ó EBM ÑÐÌֻᡢÓÐÑо¿¾­ÑéÒÔ¼°´Ù½øÒòËØË®Æ½¸ßµÄÒ½Éú£¬EBM ֪ʶµÃ·Ö¸ü¸ß£»×¨¿ÆÒ½ÉúºÍ´Ù½øÒòËØË®Æ½¸ßµÄÒ½Éú£¬EBM ʵ¼ùµÃ·Ö¸ü¸ß ¡£

ͨ¹ýÉÏÊöÑо¿½á¹û£¬ÎÒÃÇ¿ÉÒԵóöÒÔϽáÂÛ£ºÂíÀ´Î÷ÑÇÒ½ÉúµÄ EBM ֪ʶ´¦ÓÚÖеÈˮƽ£¬ÔÚ×ÊÔ´ÈÏÖª·½Ãæ´æÔÚ²î¾à£¬½üÎå·ÖÖ®Ò»µÄÒ½Éú֪ʶˮƽ½ÏµÍ£¬Õâ¿ÉÄÜ»áÓ°ÏìÁÙ´²¾ö²ßÖÊÁ¿¡¢»¼ÕßÖÎÁÆÐ§¹ûºÍÒ½ÁÆÐ§ÂÊ¡£ËäȻҽÉúÃÇ×ÔÎÒ±¨¸æµÄ EBM ʵ¼ùˮƽ½Ï¸ß£¬ÏÔʾ³öËûÃÇ¶Ô EBM µÄÈϿɣ¬µ«Êµ¼ÊµÄ EBM Ó¦Óû¹ÐèÒª¿Í¹ÛÆÀ¹À¡£ÔÚʵʩ EBM ¹ý³ÌÖУ¬´æÔÚʱ¼äÏÞÖÆ¡¢ÐÅÏ¢»ñÈ¡ÓÐÏ޺ͻ¼Õ߯«ºÃµÈÕϰ­£¬²»¹ý×éÖ¯ºÍͬʵÄÖ§³ÖÁ¦¶È½Ï´ó¡£ÁíÍ⣬½ÓÊÜ EBM Åàѵ¡¢ÓÐÑо¿¾­ÑéºÍ¸ß´Ù½øÒòËØµÄÒ½Éú£¬EBM ֪ʶˮƽ¸ü¸ß£»×¨¿ÆÒ½ÉúÇÒ´Ù½øÒòËØ¸ßµÄÒ½Éú£¬EBM ʵ¼ùˮƽ¸ü¸ß¡£

ÕâÏîÑо¿ÒâÒåÖØ´ó¡£Ëüͨ¹ý½Ï´ó¹æÄ£µÄÈ«¹úÐÔÑù±¾µ÷²é£¬¸üÈ«ÃæµØÕ¹Ê¾ÁËÂíÀ´Î÷ÑÇÒ½Éú¶Ô EBM µÄÈÏÖª¡¢Êµ¼ùºÍ´Ù½øÒòËØÇé¿ö£¬ÎªºóÐø¸Ä½øÌṩÁ˸ü¿É¿¿µÄÒÀ¾Ý¡£Í¬Ê±£¬Ñо¿Ò²Ö¸³öÁ˵±Ç°´æÔÚµÄÎÊÌâºÍ²»×㣬ΪÏà¹Ø²¿ÃźÍÈËÔ±ÖÆ¶¨Õë¶ÔÐÔ²ßÂÔÌṩÁË·½Ïò¡£±ÈÈ磬ÔÚ¸öÈ˲ãÃæ£¬¿ÉÒÔΪ·Çר¿ÆÒ½ÉúºÍȱ·¦ EBM ¾­ÑéµÄÒ½ÉúÌṩ¸ü¶àÅàѵ£»ÔÚ»ú¹¹²ãÃæ£¬¸ÄÉÆ EBM ÐÅÏ¢»ñÈ¡ÇþµÀ£¬ÓªÔìÖ§³Ö EBM µÄ×éÖ¯ÎÄ»¯£»ÔÚϵͳ²ãÃæ£¬Ìá¸ß¹«ÖÚ¶Ô EBM µÄÈÏÖª£¬½¨Á¢Ïà¹ØÐ­×÷ƽ̨µÈ ¡£Í¨¹ýÕâЩ´ëÊ©£¬¿ÉÒÔ½øÒ»²½´Ù½ø EBM ÔÚÂíÀ´Î÷ÑÇÒ½ÁÆÁìÓòµÄʵʩ£¬Ìá¸ßÒ½ÁÆÖÊÁ¿£¬×îÖÕÈû¼ÕßÊÜÒæ¡£

Ïà¹ØÐÂÎÅ
ÉúÎïͨ΢ÐŹ«ÖÚºÅ
΢ÐÅ
ÐÂÀË΢²©
  • ¼±Æ¸Ö°Î»
  • ¸ßнְλ

ÖªÃûÆóÒµÕÐÆ¸

ÈȵãÅÅÐÐ

    ½ñÈÕ¶¯Ì¬ | È˲ÅÊг¡ | м¼ÊõרÀ¸ | Öйú¿ÆÑ§ÈË | ÔÆÕ¹Ì¨ | BioHot | ÔÆ½²ÌÃÖ±²¥ | »áÕ¹ÖÐÐÄ | ÌØ¼ÛרÀ¸ | ¼¼Êõ¿ìѶ | Ãâ·ÑÊÔÓÃ

    °æÈ¨ËùÓÐ ÉúÎïͨ

    Copyright© eBiotrade.com, All Rights Reserved

    ÁªÏµÐÅÏ䣺

    ÔÁICP±¸09063491ºÅ